Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pharmesis International's interest expense for the
six
months ended in Dec. 2025 was S$ -0.06 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was S$-0.12 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pharmesis International's Operating Income for the
six
months ended in Dec. 2025 was S$ -0.76 Mil. Pharmesis International's Interest Expense for the
six
months ended in Dec. 2025 was S$ -0.06 Mil.
Pharmesis International did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Pharmesis International (SGX:BFK) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Pharmesis International's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as
Pharmesis International did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Pharmesis International Interest Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$-0.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International (SGX:BFK) has a Interest Expense of S$-0.12 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pharmesis International and its competitors.
Is Pharmesis International's Interest Expense too high?
Pharmesis International's current Interest Expense is S$-0.12 Mil. Overall, Pharmesis International has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Interest Expense compare to ZTS and UTHR?
Pharmesis International's Interest Expense of S$-0.12 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pharmesis International and its competitors. Pharmesis International's current Interest Expense is S$-0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.13 — trading 38.9% above its estimated fair value. The current Interest Expense is S$-0.12 Mil. Pharmesis International's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Interest Expense is S$-0.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmesis International (SGX:BFK) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued.
The current stock price of S$0.13 is trading 38.9% above its estimated GF Value™ of S$0.09.
GuruFocus considers Pharmesis International to be Significantly Overvalued.
Key valuation signals for SGX:BFK:
Interest Expense: S$-0.12 Mil
GF Value™: S$0.09 vs. price of S$0.13 (38.9% above fair value)
No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
32GF Score
Get the complete analysis for SGX:BFK
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:BFK has been successfully added to your 
